Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010542 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01010542 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 39 participants.
The verdict
NCT01010542, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis. Another purpose of the study is to observe how the drug enters the blood and tissues over time, how the body breaks down the drug and whether or not the body will develop an immune reaction (sensitivity) to the drug.
Interventions
- DRUG ILV-095 300 mg in a 4 to 1 ratio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-12-01 |
| Est. Completion | 2011-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010542
The ClinicalTrials.gov registry entry for NCT01010542 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ILV-095 300 mg in a 4 to 1 ratio is the first listed.
NCT01010542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01010542 about?
NCT01010542 is a clinical study titled "Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects". The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis. Another purpose of the study is to observe how the drug enters the blood and tissues over time, how the body breaks down the drug...
What is the current status of trial NCT01010542?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2009-12-01. Estimated completion is 2011-05-20.
What interventions are being tested in trial NCT01010542?
The interventions under investigation include: ILV-095 300 mg in a 4 to 1 ratio (DRUG).
Who is sponsoring clinical trial NCT01010542?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.